- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04861792
Michigan SPARC Trial (MI-SPARC)
The Michigan Sustained Patient-centered Alcohol-Related Care (MI-SPARC) Trial
Unhealthy alcohol use is a major contributor to morbidity and mortality in the US. Although effective prevention for unhealthy alcohol use and medication treatment for alcohol use disorders (AUDs) can be provided in primary care (PC), they have historically not been included in routine services. As a result, most patients do not receive evidence-based prevention or treatment for unhealthy alcohol use. Several efforts have successfully implemented alcohol-related preventive care-referred to as screening and brief intervention (SBI), but efforts to increase treatment of AUDs with medications have been less successful. Moreover, implementation efforts have usually neglected smaller PC practices, in which most PC is provided.
The Michigan SPARC trial is a partnership between Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle, bringing extensive expertise implementing evidence-based alcohol-related care, and Altarum Institute in Ann Arbor, Michigan, bringing demonstrated success engaging over 500 small to medium Michigan-based PC practices in effective quality improvement (QI) efforts. The project builds on Altarum's innovative approach to implementing new or improved clinical care using practice facilitators to provide continuing medical education and maintenance of certification (CME/MOC) programs to PC providers, along with ongoing support for QI using evidence-based implementation strategies. The KPWHRI team recently finished the highly successful AHRQ-funded Sustained Patient-centered Alcohol-Related Care (SPARC) trial using similar implementation strategies in KP Washington, including use of electronic health records and performance monitoring and feedback, and also developed a patient decision aid to support shared decision-making between patients with high-risk drinking and/or AUDs and their PC providers.
The Michigan SPARC trial combines Altarum's expertise in QI in small-medium PC practices in Michigan with KPWHRI's expertise implementing evidence-based prevention and treatment of unhealthy alcohol use-specifically alcohol SBI and medication treatment for AUDs.
Specific Aims of the Michigan SPARC trial had to be markedly modified due to the trial beginning in March 2020 at the same time as the COVID pandemic. A trial was not possible. The revised aims were to describe alcohol screening, brief intervention, AUD diagnosis and initiation of medication treatment for AUD, before and after the Michigan SPARC model was implemented, in small to medium PC practices in Michigan.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48105
- Altarum Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults age 18 years and older
- Seen in primary care at a study practice during the practice's study period
Exclusion Criteria:
• None
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Usual Care
Patients seen before the intervention launch date.
|
|
|
Experimental: Quality Improvement Intervention
Patients seen after the intervention launch date.
|
Practice facilitation, electronic health record (EHR) support, performance monitoring and feedback combined with alcohol-related continuing medical education (CME) and maintenance of certification (MOC) and tools to support alcohol related care including a decision aid for shared decision making about alcohol use disorder (AUD).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Prevention - Screening and brief intervention
Time Frame: For Aim 1 the period up to 6 months before the launch date will be compared to the 6 month period after the launch date.
|
The proportion of PC patients who screen positive for unhealthy alcohol use and have BI documented in their EHR.
|
For Aim 1 the period up to 6 months before the launch date will be compared to the 6 month period after the launch date.
|
|
Treatment - Prescription of AUD medications
Time Frame: For Aim 1 the period up to 6 months before the launch date will be compared to the 6 month period after the launch date.
|
The proportion of PC patients who are diagnosed with AUD at a visit who also receive a prescription for medications to treat AUD and are seen for follow-up within 14 days.
|
For Aim 1 the period up to 6 months before the launch date will be compared to the 6 month period after the launch date.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- R18HS027076 (U.S. AHRQ Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Deidentified data will be shared in the following ways:
External Evaluator. The Michigan SPARC investigators are committed to working with AHRQ's external evaluator (NORC) on the cross-grant evaluation.
Other data sharing. We will also make de-identified data available, upon request, after Michigan SPARC trial results are completed and published. No PC practices will be identified in the dataset. Data will be available to investigators who propose a cogent analysis not already part of planned secondary analyses. Proposals must include a biosketch of the Investigator(s), as well as research question(s), sample, measures, methods and statistical issues. Proposals will be reviewed by the Multiple PIs and the leaders of the Michigan SPARC Data and Evaluation team. For approved projects, a data sharing agreement will be developed and subsequently data will be made available.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alcohol Use Disorder (AUD)
-
University of Wisconsin, MadisonNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Not yet recruitingAlcohol Use Disorder | Alcohol Use Disorder (AUD)United States
-
Washington State UniversityRecruitingNicotine Use Disorder | Alcohol Use Disorder (AUD)United States
-
Washington State UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Not yet recruiting
-
Felix MuellerUniversity of BernRecruiting
-
Brown UniversityRecruiting
-
University of PennsylvaniaActive, not recruitingAlcoholism | Alcohol Use Disorder (AUD)United States
-
Tempero Bio, Inc.TerminatedAlcohol Use Disorder (AUD)United States
-
Boston Medical CenterNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Completed
-
University of BernRecruitingAlcohol Use Disorder (AUD) | Substance Use Disorder (SUD) | Cocaine Use Disorder (CUD)Switzerland
-
Brigham and Women's HospitalRecruitingAlcohol Use Disorder (AUD)United States
Clinical Trials on Michigan SPARC Quality Improvement Intervention
-
Helse FonnaUniversity of Bergen; KU LeuvenWithdrawn
-
Hospital do CoracaoAmgenCompleted
-
Dartmouth-Hitchcock Medical CenterMaquet Cardiovascular; LivaNova; Agency for Healthcare Research and Quality (AHRQ) and other collaboratorsCompletedCardiovascular Disease | SurgeryUnited States
-
VA Office of Research and DevelopmentCompleted
-
WHO Collaborating Centre for Maternal and Child...World Health Organization; Postgraduate Institute of Medical Education and... and other collaboratorsCompletedQuality of Hospital Care for ChildrenKyrgyzstan
-
University of North Carolina, Chapel HillNational Heart, Lung, and Blood Institute (NHLBI)CompletedHypertension | Cardiovascular Disease RiskUnited States
-
University of ManitobaManitoba HealthCompletedFrontline Staff Working Within Personal Care Home FacilitiesCanada
-
University of KentuckyNational Cancer Institute (NCI)Enrolling by invitation
-
VA Office of Research and DevelopmentActive, not recruitingIschemic Stroke | Obstructive Sleep Apnea | Transient Ischemic Attack (TIA)United States
-
VA Office of Research and DevelopmentCompletedStroke | Transient Ischemic AttackUnited States